Abstract OT2-08-01: A Prospective Phase 2 Study on Efficacy and Safety of AK105, Anlotinib Combined with Nab-Paclitaxel (Nab-P) As a First-Line Therapy in Patients(pts) with Advanced Triple-Negative Breast Cancer(tnbc)
Cancer Research（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined